TargetMol

TLC 388

Product Code:
 
TAR-T28982
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28982-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
TLC 388, a DNA topoisomerase I inhibitor, is used potentially for the treatment of Renal carcinoma and Hepatocellular carcinoma
CAS:
1432468-79-5
Formula:
C39H30N8O15
Molecular Weight:
850.71
Purity:
0.98
SMILES:
CC[C@@]1(OC(=O)C(C)ON=C2c3cc(cc(c3-c3c2cc(cc3[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O

References

1. Ghamande S, Lin CC, Cho DC, Shapiro GI, Kwak EL, Silverman MH, Tseng Y, Kuo MW, Mach WB, Hsu SC, Coleman T, Yang JC, Cheng AL, Ghalib MH, Chuadhary I, Goel S. A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. Invest New Drugs. 2014 Jun;32(3):445-51. doi: 10.1007/s10637-013-0044-7. PubMed PMID: 24271274. 2. Huang G, Wang H, Yang LX. Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog. Anticancer Res. 2010 Mar;30(3):937-44. PubMed PMID: 20393017.